ABSTRACT
INTRODUCTION
Anemia is still a major nutrition problem in developing countries. Many South-East Asia countries have higher prevalence of anemia such as Kamboja 63%, Bangladesh 47% and Indonesia 44.5% (WHO, 2015) . In Indonesia, the highest prevalence of anemia is found in pregnant women (48.2%), followed by elder people (46%), non pregnant women (45.7%), children (28.1%), and adult (16.9%) (Balitbang Kemenkes RI, 2013) . In addition, 20-30% of anemia is caused by chronic diseases including Chronic Kidney Disease (CKD) (Oliveira et al, 2014) . The prevalence of anemia in CKD patients can be as high as 58.5% if CKD patients are treated without dialysis (Cases-Amenos et al., 2014) .
The main cause of anemia in CKD is Epo deficiency which is related to decrease of erythrocyte life cycle. Deficiency of iron, vitamin and other factors can also contribute in CKD anemia [4] . As a result, the kidney volume decreases significantly in conjunction with severity of CKD, which decreases more erythropoeietin production. Epo deficiency also inhibits erythrocyte maturation from progenitor cell to normoblast and reticulocyte. Therefore, imature erythrocytes become fragile and lysis (neocytolisis). From microscopic observation, erythrocytes have normocytic and normochromic features that is different from erythrocyte features of iron deficiency anemia (Hayat et al., 2008; Mehdi & Toto, 2009 ).
According to National Kidney Foundation (2012), the standard therapy of CKD is iron supplementation, administration of erythropoiesis-stimulating agents (ESAs), and red blood cell transfusion. In Indonesia the use of ESA has increased considerably, compared to iron supplementation and blood transfusion (PERNEFRI, 2014) . Recombinant Epo and its derivatives (epoetin α, epoetin β, darbopoetin α, and methoxy polyethylene glycol-epoetin β) are the most common ESAs to treat CKD anemia (Palmer et al., 2014) .
ESAs group still have some limitations due to effectiveness and efficacy. Approximately 5% -10% of CKD patients are resistance to ESA (Johnson et al., 2007) . In addition, long-term use of ESA in rat model of CKD results in formation of anti-EPO antibodies (Garrido et al., 2012) . Administration of ESAs in CKD patients for long time also increases cardiovascular disorders like stroke, venous thromboembolism and red blood cell aplasia (Clemet et al., 2009; Parfrey et al., 2009; Palmer et al., 2010; Macdougall et al., 2014) . Because of high cost of ESAs treatment, only 20-30% of CKD patients receive ESAs prior to dialysis (National Kidney Foundation, 2012; Kim et al., 2016) .
Indonesia has 75% plants species from total 40,000 plants in the world. However, about 9,600 species are just known to have pharmacological effects (Yanuar et al., 2012) . So, the diversity of Indonesian plants can be utilized for drug development to treat various human diseases, including CKD anemia. Virtual Screening (VS) is one of the most common method of drug discovery which has some benefits such as faster, effective, and low cost (Tang and Marshal, 2011) . Molecular docking is frequently used to screen active compounds in natural resources (Ferreira et al., 2015) . Therefore, the purpose of this study was to identify molecularly Indonesian plants that have activity as an agonist for drug development of CKD anemia.
METHOD
This was a bioinformatics research study using molecular docking method. The 3-dimensional structure of erythropoietin receptors (ID: 1CN4) binding to erythropoietin was obtained from Protein Data Bank (http://www.rscb.org/pdb/) as a target protein for screening phytochemicals of Indonesian plants (http://www.herbaldb.farmasi.ui.ac.id). The 3-dimensional structure of phytochemicals was obtained from PubChem NCBI (http://pubchem.ncbi.nlm.nih.gov) and met the Lipinski's criteria [20, 21] . Software of AutoDock Tools version 1.5.6 (2013), PyRx version 0.8 (2010) and PyMol 1.7.4 was freely downloaded.
Preparation of three-dimensional structure of compound Epo-EpoR as standard
The Epo-EpoR binding complexes were separated by using AutoDock Tools and the molecular structure of Epo and EpoR was optimized by removing water molecules and adding hydrogen atoms. Due to molecular weight of Epo more than 1,500 Da, the Epo molecule was truncated into 9 parts based on binding sites on EpoR monomer 1 and monomer 2 (Table 1) . Each Epo part was validated several times with EpoR until the Root Mean Square Deviation (RMSD) score was <2 Å (Palmer et al, 2010) . Binding energy of truncated Epo-EpoR complexes was then compared to binding energy of the previous study (Syed et al, 1998) 
Docking Analysis of Phytochemicals
The PyRx applications was used to dock molecularly phytochemicals with EpoR. Phytochemicals should be interacted with residues in the binding sites of EpoR. More negative binding energy of phytochemicals-EpoR interaction was considered as candidates Epo agonist. Pymol software was used to visualize the location of phytochemicals-EpoR interaction and to compare the molecular conformation with the standard.
RESULTS AND DISCUSSION
There were nine parts of truncated homodimeric Epos (MW= 17,246.74 g/mol) which five truncated Epos were bond to EpoR monomer 1 and the remaining truncated Epos were bond to the EpoR monomer 2 ( , Ser 91 , and Ser 92 respectively except energy binding of standard 9 was lower than that of standard 4 and 8 and was higher than standard 5. Table 3 showed that all Epo standards had hydrogen and van der Walls bonds to EpoR except standard 4 and 7 which had only hydrogen bond. Standard 2 had the highest number of hydrogen bond, followed by standard 6 and 9 (4 hydrogen bonds), standard 3 with 3 hydrogen bonds and 2 hydrogen bonds in standard 8. Other standards had only one hydrogen bond. More than or equal 2 van der walls bonds were found in standard 2, standard 5, standard 6 and standard 8 while standar 3 and 9 had only one van der walls bond.
Although we used truncated Epos, these molecules similarly interact with EpoR as reported by Syed and co-workers (Syed et al, 1998) . Therefore, this docking process can be used for model of Epo-EpoR binding complexes. Total of 518 phytochemicals which was registered in HerbaldB and Pubchem met Lipinski's criteria. They were molecularly docked with EpoR and was evaluated their binding energy, location of interaction and molecule conformation. There were three phytochemicals (Indicaxanthin, Miraxanthin-V and Hexahydrocurcumin) which were similar with truncated Epo standards (table 4). They had similar molecular weight (± 300 g/mol) and lipophilicity. Similar hydrogen acceptor and donor were found in Indicaxanthin and Hexahydrocurcumin while Miraxanthin-V had higher number of hydrogen acceptor and donor, compared with Indicaxanthin and Hexahydrocurcumin. These phytochemicals had lower binding energy than binding energy of truncated Epo standards. In terms of molecule interaction, Indicaxanthin had the same interaction with EpoR as the truncated Epo standards did while 11 molecule interaction was observed in Miraxanthin-V and Hexahydrocurcumin (table 4 and 5). All phytochemicals had hydrogen and van der walls bonds but Indicaxanthin and Hexahydrocurcumin were able to interact with Phe 93 residue with van der walls bond. Indicaxanthin, Miraxanthin-V, and Hexahydrocurcumin have higher binding affinity than the standard Epo so that these phytochemicals can easily bind to EpoR. In addition, the phytochemicals have high similarity to the standard Epo. However, Indicaxanthin and Hexahydrocurcumin have an additional bond to Phe 93 residue which is play important roles in hidrophobic nature and nonpolar interactions with EpoR (Middleton et al., 1998; Singh et al., 2012 (Middleton et al, 1998; Singh et al, 2012) . It has reported that Lys 65 amino acid facilitates EpoR to interact with Epo in loops C and D and Asn 116 , a polar residue covers hydrophobic binding sites of EpoR to allow for their interaction (Barbone et al., 1997; Linvah et al., 1999) . Therefore, the additional binding sites are required for bond stability of phytochemicals to EpoR.
Because Indicaxanthin, Miraxanthin-V, and Hexahydrocurcumin have molecular weight less than 500 daltons, they can easily penetrate cell membrane of the human body. In addition, these phytochemicals have hydrogen donor <5, hydrogen acceptor <10, and high lipophilicity, which are potential as an alternative Epo agonist (Lipinski et al, 2001) .
We have firstly demonstrated that Indicaxanthin, Miraxanthin-V, and Hexahydrocurcumin potentially become a natural Epo agonist in silico. Indicaxanthin and Miraxanthin-V have antioxidant activity. Exctract of both phytochemicals have been used for treatment of thalassemia patients which decrease perferryl-Hb. Both phytochemicals are found in Mirabilis japala roots and leaves which are used for treatment tonsillitis, cystysis, and leucorrhoea (Butera et al., 2002; Tesoriere et al., 2005; . A cytotoxic effect against colorectal cancer is detected in Hexahydrocurcumin which is found in Zingiber officinale (Srimuangwong et al., 2012; . A study has reported that Zingiber officinale extracts indicate biological effects such as immunomodulator, antitumor, antiinflammation, anti-apoptosis, anti-hyperglycemia, anti-lipidemia and anti-emetics (Ali et al., 2007) .
In this study, we can not molecularly dock whole molecule of Epo with EpoR since AutoDock Vina program is unable to run high molecules (MW=>500 g/mol). This docking program is suitable for running rigid macromolecules and flexible ligands. It does not depict endogenous macromolecules that have flexible conformation. Table 5 Location of phytochemicals interaction with EpoR monomer 1 (standards 1-5) and monomer 2 (standards 6-9) compared to truncated Epos
